Recognition and management of Parkinson's disease during the premotor (prodromal) phase

Expert Review of Neurotherapeutics

Volumn 9, Issue 6, 2009, Pages 847-857

  Truong, Daniel D ^a   Wolters, Erik C ^b  

^a Parkinson's and Movement Disorder Institute   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Autonomic dysfunction; Disease modifying agents; Neuropsychiatric symptoms; Parkinson's disease; Parkinson's disease diagnosis; Premotor symptoms; Prodrome; REM sleep behavior disorder

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 6 FLUORODOPA F 18; AMITRIPTYLINE; BOTULINUM TOXIN; CITALOPRAM; CLONAZEPAM; DARIFENACIN; DOMPERIDONE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; LACTULOSE; LEVODOPA; MACROGOL; MELATONIN; MISOPROSTOL; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PHOSPHODIESTERASE V INHIBITOR; PRAMIPEXOLE; RASAGILINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILDENAFIL; SOLIFENACIN; TADALAFIL; TOLTERODINE; TROSPIUM CHLORIDE; UNINDEXED DRUG; VARDENAFIL;

AKINESIA; ANXIETY; AUTONOMIC DYSFUNCTION; BEDTIME DOSAGE; BODY POSTURE; BRADYKINESIA; CLINICAL FEATURE; COGNITIVE DEFECT; CONSTIPATION; DAYTIME SOMNOLENCE; DEMENTIA; DEPRESSION; DIET; DISEASE COURSE; DOPPLER ECHOGRAPHY; ERECTILE DYSFUNCTION; EXERCISE; GENETIC PROCEDURES; HUMAN; HYDRATION; HYPERSALIVATION; HYPOSMIA; MUSCLE RIGIDITY; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; OVERACTIVE BLADDER; PAIN; PANIC; PARASOMNIA; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PSYCHOSIS; REVIEW; SENSORY DYSFUNCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP APNEA SYNDROME; SLEEP DISORDER; SWEATING; SYMPTOM; TREMOR; UROGENITAL TRACT DISEASE; VISUAL DISORDER;

HUMANS; HYPOTENSION, ORTHOSTATIC; MENTAL DISORDERS; PARKINSON DISEASE; SYNDROME; UROLOGIC DISEASES;

EID: 67649965652     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.50     Document Type: Review

References (114)

1. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24(2), 197-211 (2003).
2. Hawkes CH. The prodromal phase of sporadic Parkinson's disease: does it exist and if so how long is it? Mov. Disord. 23(13), 1799 - 1807 (2008).
3. Koller WC. When does Parkinson's disease begin? Neurology, 42(4 Suppl. 4), 27-31; discussion 41-48 (1992).
4. Wolters E. Variability in the clinical expression of Parkinson's disease. J. Neurol. Sci. 266(1-2), 197-203 (2008).
5. Doty RL, Deems DA, Reynolds C, Stellar S. The olfactory and cognitive deficits of Parkinson's disease: evidence for independence. Ann. Neurol. 25, 166-171 (1989).
6. Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 62(5), 436-446 (1997).
7. Hawkes CH, Shephard BC, Daniel SE. Is Parkinson's disease a primary olfactory disorder? QJM 92(8), 473-480 (1999).
8. Goetz CG, Lutge W, Tanner CM. Autonomic dysfunction in Parkinson's disease. Neurology 36(1), 73-75 (1986).
9. Abbott RD, Petrovitch H, White LR et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 57(3), 456-462 (2001).
10. Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EM. Constipation in Parkinson's disease: objective assessment and response to psyllium. Mov. Disord. 12(6), 946-951 (1997).
11. Awerbuch GI, Sandyk R. Autonomic functions in the early stages of Parkinson's disease. Int. J. Neurosci. 74(1-4), 9-16 (1994).
12. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 5(3), 235-245 (2006).
13. Magerkurth C, Schnitzer R, Braune S. Symptoms of autonomic failure in Parkinson's disease: prevalence and impact on daily life. Clin. Auton. Res. 15(2), 76-82 (2005).
14. Edwards L, Quigley EM, Hofman R, Pfeiffer RF. Gastrointestinal symptoms in Parkinson disease: 18-month follow-up study. Mov. Disord. 8(1), 83-86 (1993).
15. Kaye J, Gage H, Kimber A, Storey L, Trend P. Excess burden of constipation in Parkinson's disease: a pilot study. Mov. Disord. 21(8), 1270-1273 (2006).
16. Ueki A, Otsuka M. Life style risks of Parkinson's disease: association between decreased water intake and constipation. J. Neurol. 251(Suppl. 7), vII18-vII23 (2004).
17. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci. Lett. 396(1), 67-72 (2006).
18. Oyanagi K, Wakabayashi K, Ohama E et al. Lewy bodies in the lower sacral parasympathetic neurons of a patient with Parkinson's disease. Acta Neuropathol. 80(5), 558-559 (1990).
19. Kupsky WJ, Grimes MM, Sweeting J, Bertsch R, Cote LJ. Parkinson's disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology 37(7), 1253-1255 (1987).
20. Rosenthal MJ, Marshall CE. Sigmoid volvulus in association with parkinsonism. Report of four cases. J. Am. Geriatr. Soc. 35(7), 683-684 (1987).
21. Hu G, Jousilahti P, Nissinen A et al. Body mass index and the risk of Parkinson disease. Neurology 67(11), 1955-1999 (2006).
22. Ragonese P, D'Aelio M, Callari G et al. Body mass index does not change before Parkinson's disease onset. Eur. J. Neurol. 15(9), 965-968 (2008).
23. Driver JA, Kurth T, Buring JE et al. Parkinson disease and risk of mortality. A prospective comorbidity-matched cohort study. Neurology 70(16 Pt 2), 1423-1430 (2008).
24. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-OteroJJ. A meta-anaysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann. Neurol. 52, 276-284 (2002).
25. Goldstein DS. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol. 2(11), 669-676 (2003).
26. Goldstein DS. Orthostatic hypotension as an early finding in Parkinson's disease. Clin. Auton. Res. 16(1), 46-54 (2006).
27. Fowler CJ. Urinary disorders in Parkinson's disease and multiple system atrophy. Funct. Neurol. 16(3), 277-282 (2001).
28. Kaufmann H, Nahm K, Purohit D, Wolfe D. Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies. Neurology 63(6), 1093-1095 (2004).
29. Sakakibara R, Uchiyama T, Yamanishi T, Shirai K, Hattori T. Bladder and bowel dysfunction in Parkinson's disease. J. Neural Transm. 115(3), 443-460 (2008).
30. Okun MS, McDonald WM, DeLong MR. Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity. Arch. Neurol. 59(5), 807-811 (2002).
31. Gao X, Chen H, Schwarzschild MA et al. Erectile function and risk of Parkinson's disease. Am. J. Epidemiol. 166(12), 1446-1450 (2007).
32. Borek LL, Kohn R, Friedman JH. Mood and sleep in Parkinson's disease. J. Clin. Psychiatry 67(6), 958-963 (2006).
33. Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov. Disord. 16(4), 622-630 (2001).
34. Iranzo A, Sanramaria J, Rye DB et al. Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology 65(2), 247-252 (2005).
35. Olson EJ, Boeve BF, and Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain 123 (Pt 2), 331-339 (2000).
36. Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 72, 1296-1300 (2009).
37. Hilker R, Burghaus L, Razai N, Jacobs AH, Szelies B, Heiss WD. Functional brain imaging in combined motor and sleep disorders. J. Neurol. Sci. 248(1-2), 223-226 (2006).
38. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46(2), 388-393 (1996).
39. Albin RL, Koeppe RA, Chervin RD et al. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 55(9), 1410-1412 (2000).
40. Eisensehr I, Linke R, Noachtar S, Schwarz J, Gildehaus FJ, Tatsch K. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls. Brain 123 (Pt 6), 1155-1160 (2000).
41. Uchiyama M, Isse K, Tanaka K et al. Incidental Lewy body disease in a patient with REM sleep behavior disorder. Neurology 45(4), 709-712 (1995).
42. Fabbrini G, Barbanti P, Aurilia C, Vanacore N, Pauletti C, Meco G. Excessive daytime sleepiness in de novo and treated Parkinson's disease. Mov. Disord. 17(5), 1026-1030 (2002).
43. Abbott RD, Ross GW, White LR et al. Excessive daytime sleepiness and subsequent development of Patkinson disease. Neurology 65(9), 1442-1446 (2005).
44. Wolters E, Braak H. Parkinson's disease: premotor clinico-pathological correlations. J. Neural Transm. Suppl. 70, 309-319 (2006).
45. Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 38(8), 1237-1244 (1988).
46. Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 55(2), 138-142 (1992).
47. Tissingh G, Berendse HW, Bergmans P et al. Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis. Mov. Disord. 16(1), 41-46 (2001).
48. Siderowf A, Newberg A, Chou KL et al. [99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. Neurology 64(10), 1716-1720 (2005).
49. Henderson JM, Lu Y, Wang S, Cartwright H, Halliday GM. Olfactory deficits and sleep disturbances in Parkinson's disease: a case-control survey. J. Neurol. Neurosurg. Psychiatry 74(7), 956-958 (2003).
50. Ross GW, Petrovitch H, Abbott RD et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann. Neurol. 63(2), 167-173 (2008).
51. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters ECh, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann. Neurol. 56(2), 173-181 (2004).
52. Marras C, Goldman S, Smith A et al. Smell identification ability in twin pairs discordant for Parkinson's disease. Mov. Disord. 20(6), 687-693 (2005).
53. Stamey W, Davidson A, Jankovic J. Shoulder pain: a presenting symptom of Parkinson disease. J. Clin. Rheumatol. 14(4), 253-254 (2008).
54. Braak H, Sastre M, Bohl JR, de Vos RA, Del Tredici K. Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol. 113(4), 421-429 (2007).
55. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov. Disord. 23(2), 183-189; quiz 313 (2008).
56. O'Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ. Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study. Mov. Disord. 23(1), 101-106 (2008).
57. Wolters EC, Francot CM. Mental dysfunction in Parkinson's disease. Parkinsonism Relat. Disord. 4(3), 107-112 (1998).
58. Bhattacharya K, Saadia D, Eisenkraft B et al. Brain magnetic resonance imaging in multiple-system atrophy and Parkinson disease: a diagnostic algorithm. Arch. Neurol. 59(5), 835-842 (2002).
59. Kraft E, Schwarz J, Trenkwalder C, Vogl T, Pfluger T, Oertel WH. The combination of hypointense and hyperintense signal changes on T2-weighted magnetic resonance imaging sequences: a specific marker of multiple system atrophy? Arch. Neurol. 56(2), 225-228 (1999).
60. Kraft E, Trenkwalder C, Auer DP. T2*-weighted MRI differentiates multiple system atrophy from Parkinson's disease. Neurology 59(8), 1265-1267 (2002).
61. Schrag A, Good CD, Miszkiel K et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 54(3), 697-702 (2000).
62. Warmuth-Metz M, Naumann M, Csoti I, Solymosi L. Measurement of the midbrain diameter on routine magnetic resonance imaging: a simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsy. Arch. Neurol. 58(7), 1076-1079 (2001).
63. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J. Neurol. Sci. 155(1), 60-67 (1998).
64. Benamer HT, Oertel WH, Patterson J et al. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. Mov. Disord. 18(9), 977-984 (2003).
65. Marek KL, Seibyl JP, Zoghbi SS et al. [123I] β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 46(1), 231-237 (1996).
66. 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease. Mov. Disord. 13(3), 438-445 (1998).
67. 123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. J. Neural Transm. 108(8-9), 1011-1019 (2001).
68. 123I]-FP-CIT study group. Mov. Disord. 15(3), 503-510 (2000).
69. 123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur. J. Nucl. Med. 28(3), 266-272 (2001).
70. 123I]P-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov. Disord. 17(3), 518-523 (2002).
71. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287(13), 1653-1661 (2002).
72. Winogrodzka A, Booij J, Wolters E. Disease-related and drug-induced changes in dopamine transporter expression might undermine the reliability of imaging studies of disease progression in Parkinson's disease. Parkinsonism ReUt. Disord. 11(8), 475-484 (2005).
73. 123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology 53(5), 1020-1025 (1999).
74. 123I-meta-iodobenzyl guanidine in Parkinson's disease. Nucl. Med. Commun. 19(2), 137-142 (1998).
75. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 45(1), 182-184 (1995).
76. Berg D, Godau J, Walter U. Transcranial sonography in movement disorders. Lancet Neurol. 7(11), 1044-1055 (2008).
77. Walter U, Dressier D, Wolters A, Probst T, Grossmann A, Benecke R. Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy. Neurology 63(3), 504-509 (2004).
78. Walter U, Dressier D, Wolters A, Wittstock M, Greim B, Benecke R. Sonographic discrimination of dementia with Lewy bodies and Parkinson's disease with dementia. J. Neurol. 253(4), 448-454 (2006).
79. Berg D, Merz B, Reiners K, Naumann M, Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov. Disord. 20(3), 383-385 (2005).
80. Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J. Neurol. 248(8), 684-689 (2001).
81. Walter U, Behnke S, Eyding J et al. Transcranial brain parenchyma sonography in movement disorders: state of the art. Ultrasound Med. Biol. 33(1), 15-25 (2007).
82. Walter U, Dressler D, Wolters A, Wittstock M, Benecke R. Transcranial brain sonography findings in clinical subgroups of idiopathic Parkinson's disease. Mov. Disord. 22(1), 48-54 (2007).
83. Behnke S, Berg D, Naumann M, Becker G. Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound. J. Neurol. Neurosurg. Psychiatry 76(3), 423-425 (2005).
84. Gaenslen A, Unmuth B, Godau J et al. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol. 7(5), 417-424 (2008).
85. Klein C, Schlossmacher MG. The genetics of Parkinson disease: implications for neurological care. Nat. Clin. Pract. Neurol. 2(3), 136-146 (2006).
86. Le W, Chen S, Jankovic J. Etiopathogenesis of Parkinson disease: a new beginning? Neuroscientist 15(1), 28-35 (2008).
87. Siderowf A, Stern MB. Preclinical diagnosis of Parkinson's disease: are we there yet? Curr. Neurol. Neurosci. Rep. 6(4), 295-301 (2006).
88. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55(3), 181-184 (1992).
89. Soffer EE, Metcalf A, Launspach J. Misoprostol is effective treatment for patients with severe chronic constipation. Dig. Dis. Sci. 39(5), 929-933 (1994).
90. Ney P, Pandita RK, Newgreen DT, Breidenbach A, Stöhr T, Andersson KE. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int. 101(8), 1036-1042 (2008).
91. Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N. Engl. J. Med. 342(9), 665 (2000).
92. Chancellor MB, Anderson RU, Boone TB. Pharmacotherapy for neurogenic detrusor overactivity. Am. J. Phys. Med. Rehabil. 85(6), 536-545 (2006).
93. McVary KT Clinical practice. Erectile dysfunction. N Engl. J. Med. 357(24), 2472-2481 (2007).
94. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 318(1), 121-134 (2004).
95. Gagnon J, Postuma RB, Montplaisir J. Update on the pharmacology of REM sleep behavior disorder. Neurology 67(5), 742-747 (2006).
96. Miyasaki JM, Shannon K, Voon V et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66(7), 996-1002 (2006).
97. Serrano-Duenas M. [A comparison between low doses of amitriptyline and low doses of fluoxetine used in the control of depression in patients suffering from Parkinson's disease]. Rev. Neurol. 35(11), 1010-1014 (2002).
98. Richard IH, Kurlan R. A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group. Neurology 49(4), 1168-1170 (1997).
99. Bejjani BP, Damier P, Arnulf I et al. Transient acute depression induced by high-frequency deep-brain stimulation. N. Engl. J. Med. 340(19), 1476-1480 (1999).
100. Voon V, Kubu C, Krack P, Houeto JL, Tröster AI. Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov. Disord. 21(Suppl. 14), S305-S327 (2006).
101. Cassano P, Lattanzi L, Soldani F et al. Pramipexole in treatment-resistant depression: an extended follow-up. Depress. Anxiety 20(3), 131-138 (2004).
102. Schapira AH Neuroprotection and dopamine agonists. Neurology 58(4 Suppl. 1), S9-S18 (2002).
103. Ostow M. Pramipexole for depression. Am. J. Psychiatry 159(2), 320-321 (2002).
104. Zarate CA Jr, Payne JL, Singh J et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol. Psychiatry 56(1), 54-60 (2004).
105. Naoi M, Maruyama W, Youdim MB, Yu P, Boulton AA. Anti-apoptotic function of propargyloamine inhibitors of type-B monoamine oxidase. Inflammopharmacology 11(2), 175-181 (2003).
106. Takuma K, Baba A, Matsuda T. Astrocyte apoptosis: implications for neuroprotection. Prog. Neurobiol. 72(2), 111-127 (2004).
107. Maruyama W, Akao Y, Carrillo MC et al. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol. Teratol. 24(5), 675-682 (2002).
108. Maruyama W, Takahashi T, Youdim M, Naoi M. The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J. Neural Transm. 109(4), 467-481 (2002).
109. Swanson CR, Sesso SL, Emborg ME. Can we prevent parkinson's disease? Front. Biosci. 14, 1642-1660 (2009).
110. Poewe W. Treatments for Parkinson disease - past achievements and current clinical needs. Neurology 72(7 Suppl.), S65-S73 (2009).
111. Rascol O. "Disease-modification" trials in Parkinson disease: target populations, endpoints, and study design. Neurology 72(7 Suppl.), S51-S58 (2009).
112. Olanow CW, Kieburtz K, Schapira AH. Why have we failed to achieve neuroprotection in Parkinson's disease? Ann. Neurol. 64(Suppl. 2), S101-S110 (2008).
113. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61(4), 561-566 (2004).
114. Rascol O, Olanow CW. ADAGIO: a prospective, double-blind, delayed-start study to examine the disease modifying effect of rasagiline in early Parkinson's disease (PD). Eur. J. Neurol. 15(Suppl. 3), 413 (2008).